New nanosized biocompatible MR contrast agents based on lysine-dendri-graft macromolecules.

Paramagnetic nanomaterials for use as magnetic resonance imaging (MRI) contrast agents have higher relaxivity than conventional low molecular weight MRI agents. However, the biocompatibility and pharmacokinetics of such nanomaterials will strongly affect the likelihood of clinical approval. We synthesized MRI contrast agents based on biocompatible lysine-dendri-grafts: Gd-BzDTPA-lysineG2 and Gd-BzDTPA-lysineG3. The relaxivity of Gd-BzDTPA-lysineG2 and Gd-BzDTPA-lysineG3 increased with sample temperature, while the relaxivity of Gd-BzDTPA-PAMAMG4 decreased with increasing sample temperature. The increase in relaxivity with increasing temperature may be attributed to accessibility of water to the internal Gd chelates with lysine-dendri-grafts, which does not occur with PAMAM dendrimers. Gd-BzDTPA-lysineG3 had a long intravascular half-life but were largely excreted by the kidneys. Therefore, Gd-BzDTPA-lysineG3 enhanced the blood vessels for longer periods than Gd-BzDTPA-PAMAMG4, but was still excreted through the kidney. Because of their biocompatibility, desirable magneto-physical characteristics and favorable pharmacokinetics, which are derived from different interior structures rather than the physical size, lysine-dendri-graft MR contrast agents may be feasible for clinical use.

[1]  Benjamin Thierry,et al.  Drug nanocarriers and functional nanoparticles: applications in cancer therapy. , 2009, Current drug delivery.

[2]  Shaker A Mousa,et al.  Emerging nanopharmaceuticals. , 2008, Nanomedicine : nanotechnology, biology, and medicine.

[3]  P. Choyke,et al.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. , 2008, Nanomedicine.

[4]  Claudia Weidensteiner,et al.  Physicochemical and MRI characterization of Gd3+-loaded polyamidoamine and hyperbranched dendrimers , 2007, JBIC Journal of Biological Inorganic Chemistry.

[5]  Brett A. Helms,et al.  Dendrimers at Work , 2006, Science.

[6]  A. Mohs,et al.  Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents , 2006, International journal of nanomedicine.

[7]  E. Meijer,et al.  Chemistry. Dendrimers at work. , 2006, Science.

[8]  Hisataka Kobayashi,et al.  Nano-sized MRI contrast agents with dendrimer cores. , 2005, Advanced drug delivery reviews.

[9]  D. Parker,et al.  Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI , 2004, Magnetic resonance in medicine.

[10]  Martin W. Brechbiel,et al.  Dendrimer-based macromolecular MRI contrast agents: characteristics and application. , 2003 .

[11]  M. Brechbiel,et al.  Novel intravascular macromolecular MRI contrast agent with generation‐4 polyamidoamine dendrimer core: Accelerated renal excretion with coinjection of lysine , 2001, Magnetic resonance in medicine.

[12]  J A Frank,et al.  Synthesis and relaxometry of high‐generation (G = 5, 7, 9, and 10) PAMAM dendrimer‐DOTA‐gadolinium chelates , 1999, Journal of magnetic resonance imaging : JMRI.

[13]  I. Pastan,et al.  L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. , 1996, Cancer research.

[14]  Wendy S. Becker,et al.  Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. , 1995, Cancer research.

[15]  P C Lauterbur,et al.  Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.

[16]  B. Brenner,et al.  Permselectivity of the glomerular capillary wall to macromolecules. II. Experimental studies in rats using neutral dextran. , 1975, Biophysical journal.